Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP30 | Q70CQ3 | 3/20 | 0.50 |
| ▸ | GPR119 | Q8TDV5 | 10/20 | 0.43 |
| ▸ | DPP4 | P27487 | 1/20 | 0.43 |
| ▸ | TRPV3 | Q8NET8 | 1/20 | 0.41 |
| ▸ | JAK2 | O60674 | 1/20 | 0.40 |
| ▸ | JAK3 | P52333 | 1/20 | 0.40 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.40 |
| ▸ | FPR3 | P25089 | 1/20 | 0.40 |
| ▸ | FPR2 | P25090 | 1/20 | 0.40 |
| ▸ | TACR1 | P25103 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30119908 | 1.00 | USP30 (0.50) | USP30GPR119DPP4TRPV3JAK2 | |
| SCHEMBL30119937 | 1.00 | USP30 (0.50) | USP30GPR119DPP4TRPV3JAK2 | |
| SCHEMBL29197009 | 0.87 | USP30 (0.48) | USP30GPR119DPP4TRPV3FPR3 | |
| SCHEMBL30120282 | 0.87 | USP30 (0.48) | USP30GPR119DPP4TRPV3FPR3 | |
| SCHEMBL30120522 | 0.87 | USP30 (0.48) | USP30GPR119DPP4TRPV3FPR3 | |
| SCHEMBL29197008 | 0.87 | USP30 (0.48) | USP30GPR119DPP4TRPV3FPR3 | |
| SCHEMBL3788083 | 0.84 | GPR119 (0.48) | USP30GPR119JAK2TACR1 | |
| SCHEMBL31342415 | 0.83 | GPR119 (0.40) | USP30GPR119TRPV3JAK2JAK3 | |
| SCHEMBL31548048 | 0.83 | ALDH1A1 (0.47) | USP30GPR119DPP4JAK2JAK3 | |
| SCHEMBL31342501 | 0.83 | DPP4 (0.39) | USP30GPR119DPP4TRPV3TACR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117940133-A | Therapeutic agents for degradation of mutant BRAF | C4医药公司 | 2024-04-26 | — | — | CN | disclosed |
| EP-4351583-A1 | THERAPEUTICS FOR THE DEGRADATION OF MUTANT BRAF | C4 Therapeutics, Inc. (US) | 2024-04-17 | — | — | EP | disclosed |
| WO-2022261250-A1 | THERAPEUTICS FOR THE DEGRADATION OF MUTANT BRAF | C4 THERAPEUTICS, INC. (US) | 2022-12-15 | — | — | WO | disclosed |